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Background: The availability of new pneumococcal conjugate vaccines covering a broader range of serotypes, has seen
many countries introduce these into their national immunisation program. When transitioning from 7-valent to 13-valent
pneumococcal conjugate vaccines, Australia is one of a small number of countries that included a supplementary dose of
the 13-valent pneumococcal conjugate vaccine to offer protection against additional serotypes to an expanded age
group of children. An evaluation of the implementation and uptake of the 13-valent pneumococcal conjugate vaccine
supplementary dose was undertaken in two local health districts (LHDs) in New South Wales, Australia.
Methods: A self-administered postal survey of immunisation providers in the Northern New South Wales and Mid North
Coast LHDs. Trends in vaccine ordering were examined. Coverage was assessed using data from the Australian Childhood
Immunisation Register (ACIR).
Results: Of the 177 surveys sent, 125 were returned (70%). Almost all providers (96%) were aware of the 13vPCV
supplementary dose program though took an opportunistic approach to program promotion and parental reminders.
Supplementary doses of 13vPCV were ordered for 37% of the eligible cohort, mostly in the program’s first six months.
Coverage as recorded on the ACIR was 27%, though was lower in older children and those not due for scheduled
childhood vaccines. Of the children who received the 13vPCV supplementary dose, 3% received it at the same time as
vaccines due at 12-months of age, and 44% at the time of those due at 18-months of age.
Conclusion: Despite the high awareness of the program, reported coverage was lower than that for other PCV
supplementary dose programs in Australia and internationally. This may be influenced by providers’ largely opportunistic
approach to implementation, under-reporting to the ACIR or vaccine uptake. Lessons learned from this evaluation are
relevant for future time-limited childhood vaccination programs. Prior to commencement, providers should be informed
about the importance of catch-up/supplementary vaccination for their patients and their active role in promoting this.
They should also receive program information before parents. An understanding of parental reasons for non-receipt of
time-limited childhood vaccines and evaluation of the effect of aligning supplementary (or catch up) vaccination
programs with the NIP schedule would be useful to inform future programs.
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In the last decade, vaccines have been introduced to
Australia’s National Immunisation Program (NIP) to pro-
tect children against five additional diseases [1]. In order to
maximise protection for high-risk groups and to control
disease at a population level, time-limited funding for a
‘catch-up’ series/dose or a ‘supplementary dose’ of newly in-
troduced vaccines is often provided for additional cohorts.
These programs have predominantly targeted school-aged
children and adolescents [2-5].
When 7-valent pneumococcal conjugate vaccine (7vPCV)
was introduced into Australia’s NIP for infants in 2005, the
Australian Government funded a 1-year catch-up program
in that year for children 2–23 months of age. The number
of doses required for catch-up varied depending on the age
at which the first dose had been given [6,7]. From July
2011, the 13-valent pneumococcal conjugate vaccine
(13vPCV) replaced 7vPCV in all states/territories except
the Northern Territory, where the 13vPCV replaced the 10-
valent pneumococcal conjugate vaccine (10vPCV) [8].
From October 2011 to September 2012 the Australian
Government funded a single supplementary dose of
13vPCV for children aged 12–35 months (1–3 years) who
had not received a dose of this vaccine or the 10vPCV in
their primary course [9]. This was felt to be a sufficiently
cost-effective measure to provide these children, who are at
high risk of disease, the benefit of protection from the add-
itional six serotypes covered by 13vPCV [10]. The NIP
schedule for 13PCV is 3 + 0 for non-Indigenous children
and 3 + 1 for Indigenous children in high risk states [7].
Currently, 13vPCV is approved for use in over 120 coun-
tries, 60 of which offer it as part of national or regional im-
munisation programs. [11] However, only a minority have
offered a supplementary dose of 13vPCV, mostly for chil-
dren up to five years of age. These include the United
States (vaccine not nationally funded or time-limited), Italy
(vaccine funded and not time limited) and two Canadian
provinces, Manitoba (vaccine funded and not time limited)
and Ontario (vaccine funded for 2011 only) [12-15]. In light
of this, there is considerable national and international
interest in the unique 13vPCV supplementary dose pro-
gram in Australia.
Evaluations of time-limited catch-up or supplemen-
tary vaccination programs targeting infants, either in
Australia or internationally, are limited and predomin-
antly focus on measuring vaccine coverage and the im-
pact on disease. Notwithstanding the importance of
such evidence, effective implementation is also a signifi-
cant factor influencing the success of these programs.
[16,17] This evaluation of the 13vPCV supplementary
dose program in the Northern New South Wales
(NNSW) and Mid North Coast (MNC) Local Health
Districts (LHDs) aimed to understand a) provider




A self-administered postal survey of all immunisation pro-
viders in the NNSW and MNC LHDs was undertaken to
determine awareness of the 13vPCV supplementary dose
program and approaches to implementation. Immunisa-
tion providers were defined as general practices (GP),
Aboriginal Medical Services (AMS) or community health
centres (CH) with a NSW Ministry of Health vaccine ac-
count number (VAN) and listed on public health unit
(PHU) records. These “immunisation providers” repre-
sented 93% (177/183) of all GP, AMS and CH centres in
these LHDs.
In-depth knowledge of the local immunisation coordin-
ator, together with previous Australian NIP evaluations
[18], informed the development of the survey, which was
refined following piloting with three immunisation pro-
viders outside of the NNSW and MNC LHDs. The 17-
question survey had a combination of open and closed
questions about program information received, resources
used, recall/reminder activities and notification practices to
the Australian Immunisation Register (ACIR). Surveys were
accompanied by a one-page cover letter, signed by the
Director of the North Coast PHU. They were to be
completed at the organisational level by the individual(s)
with primary responsibility for immunisation services.
Surveys were posted in March 2012 with an initial
2-week deadline for response. Non-respondents were
individually faxed a second copy 4 weeks following
the initial deadline, with end-June 2012 as the final
response cut-off.
The Northern New South Wales Medicare Local and
the North Coast PHU promoted the survey via adver-
tisements in routine newsletters and weekly faxes, emails
to lists of general practice nurses (PNs) and personal re-
minders at visits to GPs/AMSs.
Completed surveys were scanned into Cardiff Tele-
forms v10.5.2® [19], which aggregated responses for out-
put to Microsoft Excel for data cleaning. The surveys
were de-identified prior to scanning and data cleaning.
Recoding and statistical analysis were performed using
SAS Enterprise Guide v4.3 [20]. The sample was
weighted by LHD and provider type (GP, AMS, CH).
Where appropriate, response variables were collapsed
into dichotomous variables (‘yes’ or ‘no’). For questions
that used a Likert scale [21], ratings were calculated as a
percentage of those who responded to each question.
Content analysis [22] was used to generate key themes
from responses to open-ended questions. Point estimates
and 95% confidence intervals (CI) were calculated where
appropriate, with an odds ratio calculated and chi square
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p value <0.05 was considered statistically significant.
In addition to the survey, the Medicare Local and PHU
provided detailed records of the type and date of educa-
tion/promotion activities undertaken in relation to the
13vPCV supplementary dose program. Descriptive analysis
was performed on these data to determine frequency of ac-
tivity type (e.g. newsletter, face-to-face visit) and month of
implementation. Also, to determine generalisability of the
survey findings, the Rural, Remote, Metropolitan Area clas-
sification (RRMA) [23] distribution of providers in NNSW
and MNC LHDs was compared with that of NSW as a
whole. The NSW distribution was obtained from the 2012
Annual Survey of Divisions of General Practice (DGP) [24],
which classifies DGPs by RRMA. This classification was ap-
plied to postcodes of AMSs [25] and CH centres [26] in
NSW, both obtained from publicly available data.
Vaccine orders
The NSW Ministry of Health (MOH) provided line-
listings of PCV monthly orders placed by immunisation
providers with a VAN in the NNSW and MNC LHDs.
These covered the period from October 2010, 12 months
prior to commencement of the supplementary dose pro-
gram, to December 2012, the end of evaluation period
and three months after the program end-date. It was not
possible to separate orders of 7vPCV and 13vPCV or
those for the supplementary dose program vs the routine
NIP schedule. The North Coast PHU supplied the total
number of PCV doses reported as wasted per month,
from May 2011 to December 2012. The median of the
available wastage data was deducted from the raw num-
ber of doses ordered each month. The monthly orders
(less wastage) for the 12 months before and three
months after the 13vPCV supplementary dose program
were then averaged to give the ‘baseline’ ordering rate
(doses) per month. The number of additional doses or-
dered per month during the supplementary dose pro-
gram was estimated by deducting the baseline ordering
rate from the number of doses ordered for each month
of the program. Monthly totals of ordered doses (exclud-
ing wastage) were graphed to examine ordering trends
prior, during and after the 13vPCV supplementary dose
program.
PHU records of live births by LHD were used to deter-
mine the number of eligible children, by month, for the
13vPCV supplementary dose program (born 1 October
2008 to 31 December 2010).
Vaccination coverage
Vaccination coverage was assessed using data from the
ACIR as at 30 December 2012 [27]. Receipt of a supple-
mentary dose of 13vPCV was assessed for children born
1 October 2008 to 31 December 2010 (aged 12–35months) as children in this cohort were not scheduled
to receive a dose of 13vPCV in their primary course of
PCV. Receipt of a supplementary dose of 13vPCV was
defined as a fourth dose of 13vPCV recorded on the
ACIR with an administration date during the program
period. In addition, the historical average number of
13vPCV doses reported to the ACIR per month was
then subtracted from the number of doses reported each
month during the supplementary dose program period.
The remaining doses were assumed to be mis-coded
supplementary doses of 13vPCV and added into cover-
age estimates. Due to coding limitations it was not pos-
sible to exclude booster doses of 13vPCV for medically
at-risk children or to capture doses recorded under gen-
eric codes (‘other vaccine’).
Receipt of another vaccine on the same day as the
13vPCV supplementary dose was assessed by matching
administration dates for eligible children during the pro-
gram period. The method of notification to the ACIR for
reported 13vPCV supplementary doses was obtained for
the three provider types (GPs, AMSs and CHs) from
ACIR data as at 31 December 2012.
The North Coast Area Health Service Human Re-
search Ethics Committee approved this evaluation as a
quality assurance activity. It was conducted without fi-
nancial or other support from any vaccine manufactur-
ing company or individual or entity acting on behalf of
the vaccine manufacturing industry.
Results
Of the 177 surveys sent to immunisation providers, 125
were returned completed (70% response rate). Of the
remaining 52 non-returned surveys, four were not returned
due to service closure/amalgamation (4/52, 7%), five were
returned incomplete (5/52, 10%) and 43 were not returned
at all (43/52, 83%). The majority of non-responders were
GPs (40/52, 77%), most of whom had not ordered 13vPCV
during the survey period despite ordering other NIP vac-
cines during this time. Response rates did not differ signifi-
cantly between the LHDs, though were higher amongst
AMSs (10/13, 77%) and CH centres (19/20, 95%) than GPs
(96/144, 67%).
All providers in the survey sample were from the RRMA
‘rural zone’ (R1–3) [23]. The distribution of provider types
in the sample was similar to that of all rural NSW, with a
slightly higher proportion of AMSs (8% vs 2%, p < 0.0001)
and community health centres (15% vs 11%, p = 0.009).
GPs in the sample were more likely than those in NSW to
be large (≥6 doctors, 35% vs 15%, p < 0.0001) (Table 1).
GPs were the predominant immunisation provider in the
sample as well as in rural and all NSW. Immunisation-
authorised registered nurses (RNs) were the most common
health professional administering vaccines across all pro-
vider types (70/125, 56%).







General practice 96 (77)a 2712 (87) 393 (71)
Aboriginal Medical Service (AMS) 10 (8)a,b 52 (2) 28 (5)
Community Health 19 (15)a 347 (11) 130 (24)
Solo general practice 14 (15)a,b 1198 (44) 154 (39)
General practice with 2–5 doctors 42 (44) 1117 (41) 188 (48)
General practice with ≥6 doctors 34 (35)a,b 397 (15) 51 (13)
General practice with practice nurse 57 (59)a,b 1206 (45) 310 (79)
Footnotes
aStatistically significant difference (p < 0.05) between our sample and all NSW providers.
bStatistically significant difference (p < 0.05) between our sample and all providers in NSW RRMA 1–3.
Table 2 Perspectives about qualities of the information
received on the 13vPCV supplementary dose program







Timely 93 (77) 7 (6) 21 (17)
Sufficient 102 (86) 8 (7) 8 (7)
Easy to access 101 (87) 11 (10) 4 (3)
Clear 109 (93) 5 (4) 4 (3)
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electronically (86/125, 69%), though a considerable num-
ber also used a mix of paper and electronic records (25/
125, 20%) with community health centres being almost
solely paper-based. Most (101/125, 81%) respondents
used electronic patient management software, predom-
inantly Medical Director® (61/101, 60%) or Best Practice®
(24/101, 24%).
Awareness
Overall, 96% of respondents were aware of the 13vPCV
supplementary dose program (weighted n = 120), with no
significant difference by LHD or provider type. The major-
ity of respondents were made aware of the program
through up to three sources. Of those that found out about
the program from a single source (n = 22), the most com-
mon were the letter from the Australian Government Chief
Medical Officer (CMO) to providers (16/22, 57%) and the
Medicare Local newsletter (6/22, 20%); combined, these
accounted for half (18/34, 51%) of the dual sources of
awareness about the program. Other pre-defined sources
of provider awareness about the program included the
NSWMinistry of Health (MOH) website (19/125, 15%), in-
formation accompanying the vaccine delivery (41/125,
33%), the initial CMO letter to parents of eligible children
sent in September 2011 (27/125, 22%), and face-to-face
meetings held by the Medicare Local (42/125, 34%). No re-
spondents became aware of the program through social
media. For a GP, having a practice nurse (PN) did not sig-
nificantly influence awareness of the program, as overall
awareness was high.
Resources and promotion
The survey examined the use of three specific resources
to support implementation of this program: Australian
Government provider guidelines [28], NSW MOH
‘Pneumococcal for Children’ fact sheet, and a resource
pack from the vaccine supplier (Pfizer Australia Pty Ltd).
The latter included a product information card, a supple-
mentary dose program handbook for health professionals,a pad of patient information leaflets, a magnet and recall
letter template (electronic file). Just under half of respon-
dents used only one of these resources to implement the
program (59/125, 47%), most commonly the Australian
Government Provider Guidelines (44/59, 75%) or the
MOH fact sheet (8/59, 14%).
Of the providers who became aware of the program
from NSW MOH (via their website or information sent
with vaccine orders, n = 50), more than half (28/50, 56%)
reported that they did not use the MOH fact sheet. In
contrast, if providers found out about the program via
the CMO letter posted to providers they were more
likely to use the Australian Government provider
guidelines that accompanied the letter (OR 2.5, 95% CI:
1.07–5.9, p < 0.05) than those who found out about the
program from other sources. When examining atti-
tudes to information provided about the program, most
respondents agreed the information they received was
sufficient, easy to access and clear (Table 2).
One-third (42/125, 34%) of respondents did not ac-
tively promote the 13vPCV supplementary dose program
to patients. Of the two-thirds of providers who did pro-
mote the program, most used one (22/83, 27%) or two
(27/83, 33%) promotional resources. Brochures (12/35,
34%) and posters (9/35, 26%) were the most commonly
used single resources. These resources were the most
commonly used combination of resources (31/42, 74%).
The Medicare Local and North Coast PHU undertook a
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were predominantly implemented during the first two
months of the program (October 2011 = 15% and
November 2011 = 39%) and the second last month of
the program (August 2012 = 15%). The Medicare Local
included information about the program in monthly
newsletters, group emails to health professionals and
weekly faxes, all of which primarily targeted AMSs and
GPs. Some Medicare Local staff also provided verbal infor-
mation about the program at face-to-face group education
sessions (n = 11) and routine visits to GPs and AMSs. Rep-
resentatives of the vaccine supplier also visited GPs and
AMSs and provided their 13vPCV resource pack.
Reminders
Most respondents indicated they regularly sent re-
minders for routine childhood vaccination (116/125,
93%) although over three-quarters (96/125, 78%) did not
send written reminders specifically for the 13vPCV sup-
plementary dose program. This was mainly as they felt
parents already knew about the program from the CMO
letter or were told about it when they visited an immun-
isation provider for routine childhood vaccination for an
eligible child or siblings. Lack of time and staff and in-
sufficient systems for generating reminders also influ-
enced providers’ decisions not to send reminders for this
program.
Not enough available staff to provide this reminder
service; not really necessary as most parents have
received a letter and they [eligible children] are all
offered supplementary dose of Prevenar13® on
presentation to the clinic. (general practice)
Of the written parental reminders sent, all were from
GPs and were predominantly coordinated by the PN
(18/27, 66%). Reminders were mostly provided via a
mailed letter/postcard (5/27, 18%), telephone (6/27,
21%) or a combination of both (2/27, 7%). No provider
reported using short messaging services (SMS) or email
to send reminders for the 13vPCV supplementary dose
program. Irrespective of sending written reminders, the
majority of providers verbally informed parents about
this program at either the 18-month vaccination visit
(61/125, 49%) or when an eligible child presented for
any other health condition (3/125, 2%), or at both these
opportunities (28/125, 22%).
Parents of eligible children who had not had a supple-
mentary dose of 13vPCV recorded on the ACIR (as at 7
August 2012) received a personal reminder letter from
the CMO in late August 2012. Due to the timing of the
provider survey, provider awareness and experiences fol-
lowing dissemination of this letter could not be exam-
ined as part of this evaluation.Vaccine orders
Ordering trends for all PCVs in the NNSW and MNC
LHDs are presented in Figure 1. The baseline rate of
PCV ordering for the routine 2, 4 and 6-month doses
was 1346 doses per month (excluding wastage). It was
estimated that 4768 additional doses (excluding wast-
age) were ordered throughout the 12 months of the
program, covering 37% of the eligible cohort (12,981/
35,083). Almost half the additional doses (2146/4768,
45%) were ordered in the first quarter of the program
(by end-December 2011) with the majority (3719/4768,
78%) ordered by half way through the program (end-
March 2012). Peaks in ordering were observed in the
first month of the program (October 2011), prior to the
start of the school year (January 2012) and at the time
the survey was distributed (March 2012).Reporting supplementary doses
The majority of providers (119/125, 95%) reported that
they routinely notified 13vPCV supplementary doses to
the ACIR. The most common methods for this, as illus-
trated by both the ACIR and survey data, were direct
transfer from practice software/online claiming (56/119,
47%) or entered directly on the ACIR website (48/125,
40%) (Table 3).
A minority of survey respondents reported challenges
with reporting or non-reporting to the ACIR (13/125,
10%). The main challenge was the initial lack of a spe-
cific field code for 13vPCV on both patient management
software and the ACIR forms (electronic and paper).
Other reported challenges included lack of awareness or
time to report and uncertainty about how to enter the
new vaccine correctly.Coverage
Data from the ACIR indicate that 27% of the eligible co-
hort (children aged 12–35 months between October
2011 and September 2012) in NNSW and MNC LHDs
received a supplementary dose of 13vPCV during the
12 months of the program. Uptake was similar in both
LHDs (NNSW= 27.2%, MNC = 27.3%) and was lower
than the average for all NSW (32.8%, range 27.2–39.0%).
Coverage was higher in children 12–23 months of age
(36.3%) than those 24–35 months of age (14.8%). Uptake
was highest in the first two months of the program, and
then declined throughout, with an increase in the final
month of the program (Figure 2). Of those children who
received the 13vPCV supplementary dose, 3% received it
at the same time as vaccines due at 12 months of age
(first dose of measles-mumps-rubella vaccine, first dose
of meningococcal type C vaccine and fourth dose of
Haemophilus influenzae type b [Hib] vaccine). Further-
more, 44% of children who received the 13vPCV
Figure 1 Eligible cohort for the 13vPCV supplementary dose and ordering of PCV in the Northern New South Wales and Mid North
Coast Local Health Districts by month, October 2010 to December 2012.
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vaccine given at 18 months of age (varicella).
Discussion
This evaluation found high awareness of the 13vPCV sup-
plementary dose program among immunisation providersTable 3 Method of notification to the ACIR for 13vPCV supple
ACIR data at 31 December 2012







Direct transfer from practice
management software
40 – 5
Entered directly onto ACIR
secure website
47 100 85
Paper forms posted to ACIR 13 – 5
Patient lists faxed to ACIR – No data –
Telephone direct to ACIR – No data 5
Footnotes
aSurvey data is the proportion of respondents who indicated they notified supplem
bACIR data is the proportion of recorded doses of 13vPCV for each provider in thein the NNSW and MNC LHDs and providers felt they were
provided with sufficient information to support implemen-
tation. Most took an opportunistic approach to program
promotion and parental reminders. The intensity of educa-
tion and information dissemination undertaken by the
PHU and the Medicare Local decreased over the durationmentary doses from survey respondents (n = 120) and











2 59 64 47 47
75 27 26 40 39
23 8 11 8 14
No data 1 No data 1 No data
No data 5 No data 4 No data
entary doses of 13vPCV to the ACIR via each notification method.
NNSW and MNC LHDs who notified by each method.
Figure 2 Coverage as recorded on the ACIR, by month, for the supplementary dosea of 13vPCV in children born 1 October 2008 to 31
December 2010 in the Northern New South Wales and Mid North Coast Local Health Districts as at 31 December 2012. a.
‘Supplementary doses’ reported to the ACIR for eligible children during the 13vPCV supplementary dose program include fourth doses of 13vPCV
and fourth dose of 7vPCV minus the baseline number of reported fourth doses of 7vPCV per month (n=1).
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gible cohort, with almost all (78%) ordered in the program’s
first six months. Coverage as recorded on the ACIR was
low (27%), most likely reflecting a combination of under-
reporting and low uptake, the latter particularly in older
children and those not due for an NIP-scheduled vaccine.
The evaluation was conducted in two rural areas of
one Australian state with known lower than average up-
take of childhood vaccines and a higher than average
proportion of registered conscientious objectors to vac-
cination (4% vs 2.5% nationally) [29]. Despite this, com-
paring coverage in the NNSW and MNC LHDs for the
previous 7vPCV catch-up program (1–2 doses, 40%) and
the 13vPCV supplementary dose program (1 dose, 36%)
in a common target group of children (12–23 months of
age) illustrates similar uptake in both programs. Given
this and the low uptake in the United States supplemen-
tary dose program [30], findings related to program im-
plementation from this evaluation are likely to be more
broadly generalisable.
Program awareness and implementation
Only a minority of respondents remained unaware of the
13vPCV supplementary dose program. However, there were
no particular characteristics common to these providers
highlighted in the available data so their lack of awareness
may have simply been a result of the information getting
lost in the large volume of material received by primary
care providers, particularly GPs [31]. However, the level of
awareness about the program does not take into consider-
ation survey non-respondents, most of whom had notordered 13vPCV vaccine by the end of the survey period,
and who were thus likely unaware, or potentially unsup-
portive, of the 13vPCV supplementary dose program (non-
response bias) [32]. Despite this, the overall response rate
(70%) to this survey was higher than previous vaccination-
related surveys of GPs and PNs in these LHDs (47%) and
nationally (32%) [33,34].
Most providers who were aware of the program came to
know about it through multiple sources, reflecting the
provision of information by multiple stakeholders who
support NIP implementation in Australia and highlighting
the important role of the Australian Government and
Medicare Locals [35] in disseminating such information to
providers. High use of the Australian Government provider
guidelines [28] was consistent with GPs’ use of these for
the National HPV Vaccination Program [33]. Some general
practices felt more timely information was required initially,
mostly as patients presented with the CMO letter to par-
ents prior to a similar letter reaching providers. Provision of
program guidelines from the Australian Government or
via the Medicare Local with an accompanying letter to
providers about program commencement appeared to
enhance the use of these guidelines, in contrast to dis-
seminating program resources separately from initial
program information.
Most providers did not send written parental reminders
about this program, mainly as they felt the CMO letter to
parents was sufficient. Coverage data illustrate increases in
uptake at the time CMO letters were sent to parents
(September 2011 and August 2012). There is considerable
evidence of the effectiveness of personally addressed
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ation uptake [36], particularly for older children for whom
vaccination is most delayed [3]. SMS reminders are also an
efficient, cost-effective and acceptable reminder mechanism
for childhood immunisation, and have the potential to
reach low-income families and socially marginalised groups
[37-40]. In light of this and the availability and affordability
of this technology, mechanisms to enhance use of SMS re-
minders for time-limited vaccination programs should be
further explored.
Vaccine demand
Ordering data were not able to be separated by vaccine
type (7vPCV vs 13vPCV) and were only available by
month, thus limiting the assessment of trends over time
and the ability to link definitively with program-related
activities. Provider-level ordering trends could not be
identified due to considerable heterogeneity in ordering
patterns. More precise data on vaccine type was not
available and tracking of individual doses were not pos-
sible, both of which limited the capacity to determine if
an ordered dose of 13vPCV was administered as a sup-
plementary dose. Despite these limitations, ordering data
were useful to estimate the maximum uptake of the
13vPCV supplementary dose and to monitor demand for
the vaccine. Routine monitoring and feedback of order-
ing data to program implementation staff throughout a
time-limited vaccination program has the potential to fa-
cilitate timely identification of decreases in demand and
enable corrective action as required.
Linking ordering patterns to programmatic activity retro-
spectively provides valuable insight into drivers of vaccine
demand. The greatest amount of vaccine was ordered early
in the program, which is a likely reflection of the ‘newness’
of the program. Programmatic activity related to this in-
cludes initial receipt of program information by parents/
providers, providers preparing for anticipated parental de-
mand, and a peak in the number of children eligible for
vaccination. There is evidence to suggest that parental ac-
tion is greatest in the first two months following com-
mencement of a new vaccination program, thus increasing
demand, which is also seen in this program [3]. Peaks in or-
dering were also seen later in the program, including at the
start of the calendar year and when this survey was sent
directly to providers. The second reminder letter from the
CMO to parents of eligible but yet unvaccinated children
did not correspond to an increase in vaccine orders, though
an increase in vaccine uptake was observed in the month
following this. As illustrated by the plateau in ordering in
the second six months of the program, it is likely that pro-
viders had sufficient supply of 13vPCV from earlier in the
program period to meet this demand.
To boost demand outside of the start and end months of
a new time-limited vaccination program, future programsmay benefit from re-distribution of program information
and resources to providers, along with personalised re-
minders to parents of unvaccinated children. This would
ideally be done mid-way through the program and it ap-
pears the most effective method for this is direct mail from
the Government reinforced by local health staff (e.g. public
health units).
Notifying supplementary doses
The prominence of electronic notification to the ACIR, ei-
ther directly from patient management software or via the
ACIR website, is consistent with the increase in electronic
notifications nationally [27]. Although this method has its
advantages, such as less delay and reduced staff time, there
is a need to routinely verify transmission to avoid errors
which would lead to under-reporting [41]. Given the reli-
ance on electronic notification systems it is imperative that
they are updated with vaccine-specific codes prior to the
introduction of a new vaccine on the NIP. However, as
commercial companies provide patient management soft-
ware, changes in the NIP are often not reflected in the soft-
ware in a timely manner [42].
A definitive date for inclusion of a specific code for
13vPCV on the ACIR was not able to be determined,
though survey respondents reported that there were delays
in availability of this code that caused confusion for some
providers. Most commonly respondents in this situation in-
dicated they would use a generic code (‘other vaccine’) to
notify the supplementary dose of 13vPCV. Due to limita-
tions in the analysis of ACIR data, doses entered as ‘other
vaccine’ are unable to be definitively included in coverage
estimates from the ACIR, thus reducing reported coverage.
However, explorative examination of the ‘other vaccine’ cat-
egory on the ACIR indicates this would not fully account
for the low reported coverage, which is most likely due to a
combination of low uptake and under-reporting.
Under-reporting is a known limitation of the ACIR data,
though the extent of this in recent years and for catch-up
or supplementary dose vaccination programs is not cur-
rently known [43]. The difference between ACIR coverage
(27%) and the estimated proportion of the eligible cohort
for which 13vPCV supplementary doses were ordered
(37%) was most likely due to under-reporting of doses ad-
ministered or wasted. This difference is higher than avail-
able estimates of under-reporting for routine childhood
vaccines (2–3%) [29,43,44]. This may be due to the per-
ceived ‘optional’ nature of the supplementary dose and it
not being linked to parental immunisation incentive pay-
ments. Another reason may be inaccurate recording on the
ACIR due to the lack of a vaccine-specific code, thus limit-
ing usefulness of electronic notification methods. A
provider-level audit would be useful to more accurately de-
termine the nature and extent of under-reporting for rou-
tine, catch-up and supplementary vaccination in Australia.
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The 13vPCV supplementary dose program provides pro-
tection for the six additional pneumococcal serotypes
not covered in 7vPCV. As over 90% of children would
have some protection against pneumococcal disease
from their primary course of 7vPCV [45], there could be
variability in the perception of parents and health pro-
fessionals about the importance of protection from the
additional serotypes [29]. The slightly higher coverage
achieved in the 7vPCV catch-up program (12–23 month
age group 40% vs 36%), which was the first pneumococ-
cal vaccine universally introduced onto the NIP, provides
some evidence to support this.
Uptake of the 13vPCV supplementary dose was higher in
younger (aged 12–23 months) than older (aged 24–35
months) eligible children. This has also been observed in
the United States (12–23 months of age 58% vs 24–59
months of age 32%) where reasons for this are thought to
include parental perception of a greater disease risk in
younger children and these children having more oppor-
tunities for vaccination as they visit health providers more
frequently than older children [30]. This may also be the
case in Australia where routine vaccination and health as-
sessments primarily target children under 18 months and
3.5–4 years of age [46,47]. Therefore, offering the 13vPCV
supplementary dose opportunistically when children pre-
sented for another health condition/vaccine and/or visited
the immunisation provider with siblings would not have
captured all eligible children.
Several comments from the provider survey illustrated
circumstances where parents declined the 13vPCV supple-
mentary dose as it was ‘another vaccine’ at 12 months of
age. However, offering the 13vPCV supplementary dose at
the 18-month NIP schedule point appeared effective, with
nearly half (44%) of the children recorded on the ACIR as
receiving a 13vPCV supplementary dose also received their
18-month NIP vaccine at the same time. The time and cost
involved in making a separate appointment for a supple-
mentary vaccine and having only one other vaccine admin-
istered concurrently were likely incentives for concurrent
administration at 18 month NIP schedule point. Parental
attitudes towards the 13vPCV supplementary dose program
and reasons for non-vaccination were not in the scope of
this evaluation, though would be beneficial to understand
in order to further explain reasons for low uptake.
Conclusion
Despite a high level of provider awareness, use of na-
tional resources to implement the program and reported
high rates of electronic notification of administered
doses to the ACIR, uptake of the 13vPCV supplementary
dose was lower than for other comparable PCV catch-up
vaccination programs. This was influenced by several
factors, including; providers’ opportunistic approach toimplementation, under-reporting of administered vac-
cines to the ACIR and parents’ passively or actively de-
clining vaccines for their child.
This evaluation highlights several factors to consider
when implementing future time-limited vaccination pro-
grams. Prior to vaccine distribution, it is important to en-
sure provision of program information to providers before
patients. A follow-up targeted mail-out of key program in-
formation and resources mid-way through the program is
likely to enhance demand. To facilitate notification, timely
addition of vaccine-specific codes to reporting forms/soft-
ware is important, as is educating providers about the im-
portance of, and correct way to, report administered
vaccines. Given the high proportion of eligible children
vaccinated in the first six months of the program, consider-
ation should be given to the duration of catch-up and sup-
plementary dose programs, though this has to be weighed
against cost-effectiveness and provision of ample oppor-
tunity for vaccination. Further evaluation of the effect of
aligning supplementary (or catch up) vaccination programs
with the NIP schedule is needed. This should include re-
view of national data on timing of vaccine receipt as well
as the effect on parents need to return for a separate ap-
pointment and prospects for opportunistic vaccination.
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